XML 81 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenue:        
Total revenue $ 6,392,000 $ 5,599,000 $ 16,630,000 $ 13,681,000
Costs and expenses:        
Cost of revenue 6,068,000 6,603,000 16,753,000 17,266,000
Selling, general and administrative (including stock based compensation) 3,558,000 3,667,000 10,261,000 10,702,000
Total costs and expenses 9,626,000 10,270,000 27,014,000 27,968,000
Operating loss (3,234,000) (4,671,000) (10,384,000) (14,287,000)
Other income (expense):        
Interest income 9,000 28,000 42,000 331,000
Dividend income 4,000 4,000
Other income (expense) 2,000 10,000 39,000
Interest expense (38,000) (53,000) (194,000) (242,000)
Foreign Currency Translation Adjustment (1,000) 8,000 (1,000) (5,000)
Gain on extinguishment of debt 595,000 595,000
(Loss)/gain on equity method investment 2,000 (4,000) (4,000) 3,000
Gain (loss) on investments 477,000 (449,000) 1,105,000 (1,021,000)
Impairment of intangible assets (600,000)
Provision for loan losses (562,000) (908,000)
(Loss)/gain on sale (43,000) (727,000) 165,000
Loss from operations before income taxes (2,229,000) (5,701,000) (10,154,000) (15,925,000)
Income tax benefit 67,000 163,000
Net loss (2,229,000) (5,701,000) (10,087,000) (15,762,000)
Income (loss) from operations attributed to noncontrolling interest (70,000) 418,000 903,000 1,728,000
Net loss attributable to DSS common stockholders $ (2,299,000) $ (5,283,000) $ (9,184,000) $ (14,034,000)
Loss per common share attributable to common stockholders        
Basic $ (0.25) $ (0.75) $ (1.03) $ (1.99)
Diluted $ (0.25) $ (0.75) $ (1.03) $ (1.99)
Shares used in computing loss per common share:        
Basic 9,092,518 7,066,772 8,957,482 7,066,772
Diluted 9,092,518 7,066,772 8,957,482 7,066,772
Printed Products Revenue [Member]        
Revenue:        
Total revenue $ 4,994,000 $ 4,828,000 $ 13,249,000 $ 11,429,000
Rental Revenue [Member]        
Revenue:        
Total revenue 718,000 496,000 2,147,000 1,334,000
Net Investment Revenue [Member]        
Revenue:        
Total revenue 7,000 45,000 36,000 181,000
Commission Revenue [Member]        
Revenue:        
Total revenue 662,000 230,000 1,166,000 737,000
Biotechnology Retail Revenue [Member]        
Revenue:        
Total revenue $ 11,000 $ 32,000